Eprenetapopt

N/A

Report date: 2023/05/05 17:38:51
NME

Base Information

Drug NameEprenetapopt
Drug Alias NameUNII-Z41TGB4080PRIMA-1METAPR-246
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTumor protein p53 stimulantsApoptosis inducers
TargetsTumor protein p53
Therapy Area/IndicationsSolid tumoursMyeloproliferative DisordersMyelodysplastic Syndromes +[18
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesSweden +[8
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAprea Therapeutics Ab
China Registration ClassN/A

Develop Information

Active IndicationsSolid tumoursMyeloproliferative DisordersMyelodysplastic Syndromes +[10
Inactive IndicationsProstatic NeoplasmsHematologic NeoplasmsOvarian Neoplasms +[8

Other Information

ATC CodeN/A
Related LinksN/A